An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
(wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
National University Corporation Tokai National Higher Education and Research System (Japan)
Inventor
Iwai, Hiroto
Homma, Masakazu
Atago, Takayuki
Yamamoto, Junichiro
Abe, Hiroshi
Kimura, Yasuaki
Abstract
The present invention relates to a polynucleotide, containing a translated region from a start codon to a stop codon, a 5′ untranslated region, and a poly A chain, in which 65% or more of nucleotides contained in the poly A chain are sugar-modified nucleotides.
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
4.
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND
Provided is a prophylactic and/or therapeutic agent for kidney diseases. The present invention provides a prophylactic and/or therapeutic agent for kidney diseases (for example, chronic kidney disease, acute kidney failure, or the like) that contains a compound represented by general formula (I) (wherein all the symbols are as defined in the description) or a salt thereof.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
5.
METHODS FOR TREATING HYPERTENSION USING AN ANTI-BMP10 MONOCLONAL ANTIBODY OR FRAGMENT THEREOF
An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.
The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
An object of the present invention is to provide a culture method by which an LMWS amount is minimized while high productivity of a target protein is maintained. The present invention relates to a method for preventing generation of a degradation product (a low molecular weight species: LMWS) of a target protein. The method includes: a means for, in a cell culture process for producing the target protein at a high concentration in a culture medium, removing a reactive oxygen species in the culture medium.
An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to a composition which contains an intestinal bacterium belonging to the genus Veillonella and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
The present invention relates to a composition which contains an intestinal bacterium belonging to Bacteroidetes and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
A synthetic adsorbent, where a maximum value of a differential pore volume under a pressure condition of 0.5 to 30.0 psia is greater than 0.05 mL/g. A method of measuring the differential pore volume includes reducing a pressure in a sample container where the synthetic adsorbent that has been dried is placed to 10 Pa or less, mercury is degassed by reducing the pressure to 10 Pa or less, and the sample container is filled with the mercury at a pressure of 0.5 psia, measuring a mercury intrusion amount when the pressure in the sample container filled with the mercury is increased from 0.5 to 30.0 psia, and calculating the differential pore volume by dividing an amount of an increase in the mercury intrusion amount when a first-stage pressure calculated based on the mercury intrusion amount measured in the measuring is increased, by a measured amount of the synthetic adsorbent.
The present invention provides a method for producing a compound represented by formula (I), the method including a step that reacts a compound represented by formula (II) with a compound represented by formula (III).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
The purpose of the present invention is to provide a bispecific antibody containing an antigen-binding domain which binds to CD40 and an antigen-binding domain which binds to the Epithelial Cell Adhesion Molecule (EpCAM). This invention pertains to a bispecific antibody containing an antigen-5 binding domain which binds to CD40 and an antigen-binding domain which binds to EpCAM.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
16.
ANTI-FGF23 ANTIBODY, AND FRAGMENT OF SAID ANTIBODY
The present invention pertains to: an antibody which binds to FGF23 and in which, with respect to an antibody that includes a heavy chain variable region (hereinafter, referred to as VH) having an amino acid sequence indicated in SEQ ID NO. 1 and a light chain variable region (hereinafter, referred to as VL) having an amino acid sequence indicated in SEQ ID NO. 2, at least the amino acid residue at positon 100 or the amino acid residue at position 105 in the amino acid sequence indicated in SEQ ID NO. 1 for VH is substituted with another amino acid residue; and a fragment of the antibody.
A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An object of the present invention is to provide a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present disclosure relates to an anti-OX40 antibody for use in treatment or prevention of OX-40 related diseases such as atopic dermatitis. In particular, the present disclosure provides an administration schedule that treats atopic dermatitis with an anti-OX40 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japan)
KYOWA KIRIN CO., LTD. (Japan)
Inventor
Nagata Satoshi
Ise Tomoko
Kamada Haruhiko
Sato Hidetaka
Tokunaga Akihiro
Matsubara Masahiro
Namisaki Hiroshi
Yamada Takenao
Abstract
The present invention relates to: a monoclonal antibody or a fragment thereof that binds to an extracellular region of FCRL1; a hybridoma that produces the antibody; a nucleic acid having a base sequence that encodes the antibody or a fragment of the antibody; cells transformed by a vector including the nucleic acid; a method for producing the antibody or a fragment of the antibody, the method using the hybridoma or the transformed cells; an antibody-drug conjugate including the antibody or a fragment of the antibody; a therapeutic drug and a diagnostic drug which include the antibody or a fragment of the antibody; and a method for treating and a method for diagnosing an FCRL1-related disease which use the antibody or a fragment of the antibody or an antibody-drug conjugate including the antibody or a fragment of the antibody.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method for selecting a cell strain in which reduction of a recombinant protein is suppressed, and uses of the selected cell are disclosed. The method for selecting a cell, includes a first step: measuring the expression level of a gene in a cell, the gene being at least one gene selected from genes comprising any one of the base sequences represented by SEQ ID NOS: 1 to 16 or orthologous genes thereof; and a second step: comparing the expression level of the gene measured in the first step with a control value of the expression level of the gene in a control cell, and evaluating the expression level capable of suppressing reduction of a recombinant protein based on a difference therebetween.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
23.
PHARMACEUTICAL COMPOSITION FOR BLOOD CELL RECOVERY AFTER CORD BLOOD TRANSPLANT
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition is characterized by being administered starting the day after the transplant. The present invention also relates to a method for treating an allogeneic cord blood transplant recipient using the pharmaceutical composition.
The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I):
The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I):
The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I):
(wherein
R6 and R7 may be the same or different and each represent a hydrogen atom or the like,
R8, R9, R10, and R11 may be the same or different and each represent a hydrogen atom or the like,
R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and
R3 represents optionally substituted aryl or an optionally substituted heterocyclic group).
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
An object of the present invention is to provide an antibody composition, which exhibits an effector function more specifically for a target cell coexpressing two types of antigens that are different from each other and damages the target cell, and also can maintain affinity for the individual target antigens sufficiently high. The present invention relates to an antibody composition against a first antigen and a second antigen that are different from each other, including a first IgG half-molecule and a second IgG half-molecule and relates to the first IgG half-molecule and the second IgG half-molecule constituting the antibody composition.
A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
C07D 215/44 - Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
28.
Methods for treating hypertension using an anti-BMP10 monoclonal antibody or fragment thereof
An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.
National University Corporation Tokai National Higher Education and Research System (Japan)
Kyowa Kirin Co., Ltd. (Japan)
Inventor
Abe, Hiroshi
Iwai, Hiroto
Homma, Masakazu
Asano, Kana
Harada, Kenji
Yamamoto, Junichiro
Shinohara, Fumikazu
Motosawa, Keiichi
Kimura, Yasuaki
Nakamoto, Kosuke
Abstract
An object of the present invention is to provide a polynucleotide having a modification site in a translated region with translation activity retained. The object can be achieved by a polynucleotide containing a translated region from a start codon to a stop codon, in which the translated region contains n codons, and the n is a positive integer of 2 or more, each of the n codons contains first, second and third nucleotides, and the first nucleotides in at least two codons of the n codons are sugar modified nucleotides.
An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The purpose of the present invention is to provide a bispecific antibody and a fragment of said bispecific antibody that have an agonist activity against GM-CSF receptors. The present invention relates to a bispecific antibody, or a fragment of said bispecific antibody, including a first antigen binding domain and a second antigen binding domain, wherein one of the first antigen binding domain and the second antigen binding domain is an antigen binding domain that binds to CD116, and the other is an antigen binding domain that binds to CD131.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 43/00 - Drugs for specific purposes, not provided for in groups
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
Inventor
Iwai, Hiroto
Homma, Masakazu
Atago, Takayuki
Yamamoto, Junichiro
Abe, Hiroshi
Kimura, Yasuaki
Abstract
The present invention relates to a polynucleotide including a translation region from a start codon to a stop codon, a 5' untranslated region, and a poly-A tail, 65% or more of the nucleotides that constitute the poly-A tail being sugar-modified nucleotides.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/67 - General methods for enhancing the expression
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
Inventor
Iwai, Hiroto
Homma, Masakazu
Atago, Takayuki
Yamamoto, Junichiro
Abe, Hiroshi
Kimura, Yasuaki
Abstract
The present invention relates to a polynucleotide including a translation region from a start codon to a stop codon, a 5' untranslated region, and a poly-A tail, 65% or more of the nucleotides that constitute the poly-A tail being sugar-modified nucleotides.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/67 - General methods for enhancing the expression
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
34.
SYNTHETIC ADSORBENT, ANTIBODY PURIFICATION METHOD, AND ANTIBODY PRODUCTION METHOD
In this synthetic adsorbent, the maximum value of a differential pore volume (mL/g) determined under pressure conditions from 0.5 psia to 30.0 psia as measured by the following method exceeds 0.05 mL/g. 1. The pressure in a sample container including the synthetic adsorbent being dried is reduced to 10 Pa or lower, and mercury as prescribed in JIS K8572 is degassed by reducing pressure thereof to 10 Pa or lower and is loaded in the sample container at a pressure of 0.5 psia. 2. The mercury intrusion amount is measured while the pressure in the sample container loaded with the mercury is incrementally raised from 0.5 psia to 30.0 psia. 3. The differential pore volume (mL/g) is determined by dividing, by a measured synthetic adsorbent amount, the increase amount of the mercury intrusion amount when the pressure is increased by a one-step pressure calculated on the basis of the mercury intrusion amount measured in 2 above.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
B01D 15/00 - Separating processes involving the treatment of liquids with solid sorbentsApparatus therefor
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
wherein L1 and L2 are the same or different and each represents a small molecular ligand for BET protein, and S represents a group represented by a formula selected from the group consisting of formulas (S1) to (S18).
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
An object of the present invention is to provide a DcR3 variant that has binding activity (preferably neutralizing activity) to a ligand of DcR3, and that results in a decreased amount of aggregates as compared to wild-type DcR3 when produced using a cell derived from a mammal as a host, and/or that exhibits improved in vivo kinetics; a DNA encoding the DcR3 variant; a vector including the DNA; a transformant obtained by introducing the vector; a method for producing a variant using the transformant; and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease including the variant as an active ingredient, and, in order to achieve the object, the present invention provides a DcR3 variant including a part of DcR3 and a part of a TNF superfamily molecule.
The purpose of the present invention is to provide a culture method by which the amount of low molecular weight species (LMWS) is minimized while maintaining high productivity of a target protein. The present invention pertains to a method for suppressing the formation of degradation products (LMWS) of a target protein, said method comprising a means for, in a cell culture process for producing the target protein at a high concentration in a culture medium, removing reactive oxygen species in the culture medium.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
An object of the present invention is to provide, as a method for producing an antibody at a lower cost than the prior art, a method for purifying an antibody in a non-adsorption mode using an inorganic compound containing silicon dioxide and aluminum oxide, a method for producing an antibody comprising the purification method, and an antibody produced by the production method, and the like. The present invention relates to a method for purifying an antibody in a non-adsorption mode using an inorganic compound containing silicon dioxide and aluminum oxide, a method for producing an antibody comprising the purification method, and an antibody produced by the production method.
The present invention pertains to: a composition that comprises an intestinal bacterium belonging to the phylum Bacteroides and having an inflammation reducing effect or a substance derived from the intestinal bacterium and having an inflammation reducing effect, and that has at least one effect selected from among anti-inflammatory, immunomodulatory, epithelial barrier repair, IL-10 induction and IL-22 induction effects; and an ameliorating agent for inflammatory, autoimmune or infectious diseases that comprises the aforesaid intestinal bacterium or a substance derived from the intestinal bacterium and having an inflammation reducing effect.
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a composition that includes an intestinal bacterium belonging to the genus Veillonella having an inflammation-suppressing action or a substance having an inflammation-suppressing action derived from said intestinal bacterium and has at least one action selected from an anti-inflammatory action, an immunomodulatory action, an epithelial barrier repair action, an IL-10 inducing action, and an IL-22 inducing action and to an improving agent for an inflammatory disease, an autoimmune disease, or an infection that includes said intestinal bacterium or a substance having an inflammation-suppressing action derived from said intestinal bacterium.
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Collection and computerized management of clinical data
related to clinical trials of pharmaceuticals in medical
institutions; administrative management of various clinical
data of patients. Providing information about the results of clinical trials
for pharmaceuticals; research in the field of
pharmaceuticals; providing information on research in the
field of pharmaceuticals; testing, inspection or research of
pharmaceuticals, cosmetics or foodstuffs. Medical analysis of information on various clinical data of
patients; provision of information on various clinical data
of patients; provision of medical information.
An object of the present invention is to provide a bispecific antibody, which binds to CD40 and FAP and exhibits a strong CD40 agonistic activity in a FAP dependent manner or a bispecific antibody fragment thereof, and the like. The present invention relates to a bispecific antibody, which is a bispecific antibody containing an IgG portion including a first antigen binding domain and also containing a second antigen binding domain, and binding to human CD40 and human FAP, wherein the C terminus of a heavy chain of the IgG portion binds to the second antigen binding domain either directly or via a linker, or a bispecific antibody fragment thereof, and the like.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An object of the present invention is to provide a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3. The present invention relates to a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment, a vector containing the DNA, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A composition containing antithrombin and a method for treating preeclampsia are disclosed. The method includes administering antithrombin or a composition including antithrombin to a subject in need of preeclampsia treatment. The subject may have blood antithrombin activity of 100% or less. The composition containing antithrombin may be administered to a subject with preeclampsia, who has blood antithrombin activity of 100% or less and the like.
A therapeutic agent for Parkinson's disease containing istradefylline as an effective ingredient being characterized in exhibiting more expression of a shortening effect of the OFF time by administration to a patient of Parkinson's disease of 65 or more years old as compared with administration to a patient of Parkinson's disease of younger than 65 years old.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Electronic data collection of clinical data related to clinical trials of pharmaceuticals in medical institutions for business purposes and computerized management of clinical data related to clinical trials of pharmaceuticals in medical institutions; computerized management of various clinical data of patients Providing medical and scientific research information about the results of clinical trials for pharmaceuticals; pharmaceutical research; providing pharmaceutical research information; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs Medical analysis of information on various clinical data of patients for diagnosis, treatment, long-term disease prognosis, and medical research purposes; provision of medical information relating to various clinical data of patients; provision of medical information
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Collection and computerized management of clinical data related to clinical trials of pharmaceuticals in medical institutions; administrative management of various clinical data of patients.
(2) Providing information about the results of clinical trials for pharmaceuticals; research in the field of pharmaceuticals; providing information on research in the field of pharmaceuticals; testing, inspection or research of pharmaceuticals, cosmetics and foodstuffs.
(3) Medical analysis of patients clinical data for diagnosis, treatment, epidemiology, long-term disease prognosis, and medical research purposes in the fields of bone and mineral metabolism, endocrinology, nephrology, orthopedics, pediatric, oncology, central nervous system and immunology; provision of information on clinical data of patients for diagnosis, treatment, epidemiology, long-term disease prognosis, and medical research purposes in the fields of bone and mineral metabolism, endocrinology, nephrology, orthopedics, pediatric, oncology, central nervous system and immunology; providing information in the fields of bone and mineral metabolism, endocrinology, nephrology, orthopedics, pediatric, oncology, central nervous system and immunology for diagnosis, treatment, epidemiology, long-term disease prognosis, and medical research purposes.
The present invention provides compositions and methods for treating tumor-induced osteomalacia. The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and/or infiltration into target tissue and/or proliferation in the tissue of eosinophils and/or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a nucleic acid conjugate represented by the following formula 1:
The present invention provides a nucleic acid conjugate represented by the following formula 1:
The present invention provides a nucleic acid conjugate represented by the following formula 1:
wherein X is a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs, wherein in the double-stranded nucleic acid, an oligonucleotide strand having a chain length of 17 to 30 nucleotides in the antisense strand is complementary to any of target APCS mRNA sequences described in Tables 1-1 to 1-13, and the 3′ end or the 5′ end of the sense strand binds to S3, L1 and L2 are each independently sugar ligand, and Si, S2 and S3 are each independently a linker.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
The present disclosure relates to an anti-OX40 antibody for use in treatment or prevention of OX-40 related diseases such as atopic dermatitis. In particular, the present disclosure provides an administration schedule that treats atopic dermatitis with an anti-OX40 antibody.
The present disclosure relates to an anti-OX40 antibody for use in treatment or prevention of OX-40 related diseases such as atopic dermatitis. In particular, the present disclosure provides an administration schedule that treats atopic dermatitis with an anti-OX40 antibody.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; Pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, agents for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids; hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, Crohn's disease, and chronic active hepatitis; estrogen and progesterone preparations used as combined oral contraceptives; urinary antiseptics, analgesics, anti-itching agents; cataplasms for the treatment of bruises, lumbago and stiff shoulder; pharmaceutical preparations used to treat hair disorders; vitamin preparations; food enriching agents, namely, vitamin supplements, for treating vitamin deficiencies; anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa rolls and sticks for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; antiseptics, drugs for treating arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs for treating Parkinson's disease; pharmaceuticals, namely, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances, nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations; diuretic and anti-hypertensive preparations; in vitro diagnostic reagents for medical use; in vitro extra corporeal diagnostic reagents for medical use; in vitro x-ray contrast agents for medical use; in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases
58.
THERAPEUTIC AGENT FOR A TUMOR COMPRISING AN IDO INHIBITOR ADMINISTERED IN COMBINATION WITH AN ANTIBODY
The present invention provides a method for treating a tumor comprising administering an effective amount of an antibody which specifically binds to human CC chemokine receptor 4, human epidermal growth factor receptor 2, human CD20, or epidermal growth factor receptor, and an indoleamine 2,3-dioxygenase inhibitor to a human in need thereof, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cancer or malignant tumors, pain, hematological disorders, renal disease, endocrine diseases, immunity disorders, neurological, psychiatric and other central nervous system disorders; pharmaceutical preparations for supportive care in the treatment of cancer or malignant tumors; diagnostic preparations for medical laboratory use; diagnostic preparations for clinical laboratory use; diagnostic chemical reagents for medical purposes; cells for medical laboratory use; bacteriological culture mediums for medical and veterinary purposes; cell culture mediums for medical laboratory use; reagent paper for medical purposes.
60.
HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME
The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a bispecific antibody in which an N-terminal side polypeptide is bound to an IgG portion that binds to TfR, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to a method for preparing a liquid medium which is characterized by dissolving a desired component efficiently by controlling an amount of supplied oxygen, a liquid medium prepared by the preparation method, a method for culturing cells using the liquid medium prepared by the preparation method, a method for producing a physiologically active substance having desired quality using the culture method, and a physiologically active substance having desired quality produced by using the production method.
The purpose of the present invention is to provide a bispecific antibody that binds to human GPC3 and human TfR, a fragment of the bispecific antibody, etc. The present invention pertains to: a bispecific antibody that binds to human GPC3 and human TfR; a fragment of the bispecific antibody; a nucleic acid containing a base sequence that encodes the bispecific antibody or the bispecific antibody fragment; a vector containing the nucleic acid; a transformant strain producing the bispecific antibody or the bispecific antibody fragment; a method for producing the bispecific antibody or the bispecific antibody fragment; a therapeutic agent and/or a diagnostic agent containing the bispecific antibody or the bispecific antibody fragment; a therapeutic method and/or a diagnostic method using the bispecific antibody or the bispecific antibody fragment; and a detection or assay reagent containing the bispecific antibody or the bispecific antibody fragment.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
An object of the present invention is to provide an antibody composition, which more selectively exhibits an effector function against a target cell coexpressing two types of antigens that are different from each other and damages the target cell, and also can maintain affinity for the individual target antigens sufficiently high. The present invention relates to an antibody composition against a first antigen and a second antigen that are different from each other, composed of a first IgG half-molecule and a second IgG half-molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
65.
PHARMACEUTICAL COMPOSITION FOR TREATING APLASTIC ANEMIA
The present invention relates to a pharmaceutical composition for treating aplastic anemia, which comprises Romiplostim as an active ingredient, wherein the pharmaceutical composition is administered subcutaneously once a week, wherein Romiplostim is administered at 10 μg/kg/week for 4 weeks from the start of administration, administered at more than 10 μg/kg/week and at a maximum of 20 μg/kg/week after week 5.
An object of the present invention is to provide a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to an epithelial cell adhesion molecule (EpCAM). The present invention relates to a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to EpCAM.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
An antibody or antigen binding fragment thereof that binds to an IL-36, wherein the antibody or antigen binding fragment thereof binds to both IL-36α and IL-36γ, and wherein the antibody is an antagonist of both IL-36α and IL-36γ.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I):
n1 and n2 are the same or different, and each represents 0 or 1].
C07D 311/68 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Although there are existing therapeutic agents for treating diseases caused by an abnormal increase of cAMP in the brain, such as hyperkinesia, chorea, dystonia (muscle tension abnormality) and myoclonus, the effect thereof is inadequate, and a therapeutic medication having a new mechanism is needed. The present invention provides a therapeutic agent for hyperkinesia, which contains istradefylline as an active ingredient, and a treatment method for hyperkinesia, which includes administering an effective amount of istradefylline to a subject.
The purpose of the present invention is to provide an antibody composition which exerts an effector function more specifically on target cells co-expressing two different antigens and damages the target cells, and which can maintain a sufficiently high affinity for individual target antigens. The present invention pertains to: an antibody composition which is composed of a first IgG halfmer and a second IgG halfmer and against a first antigen and a second antigen that are different from each other; and a first IgG halfmer and a second IgG halfmer that constitute said antibody composition.
An object of the present invention is to provide a method of enabling efficient structural analysis of a target protein that has been impossible or difficult to analyze so far, by stabilizing the target protein. The present invention provides an anti-BRIL antibody which specifically binds to BRIL or a BRIL fusion protein and an antigen-binding fragment thereof, a nucleic acid encoding the anti-BRIL antibody and the antigen-binding fragment thereof, a vector containing the nucleic acid, an antibody producing cell containing the vector, a method of producing the antibody, and a method of using the antibody in a protein structural analysis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The purpose of the present invention is to provide an antibody composition which exerts an effector function more specifically on target cells co-expressing two different antigens and damages the target cells, and which can maintain a sufficiently high affinity for individual target antigens. The present invention pertains to: an antibody composition which is composed of a first IgG halfmer and a second IgG halfmer and against a first antigen and a second antigen that are different from each other; and a first IgG halfmer and a second IgG halfmer that constitute said antibody composition.
The present invention provides a compound represented by formula (I) usable as a cationic lipid that facilitates introduction of a nucleic acid, for example, into a cell, and a composition or the like containing the compound.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 9/00 - Medicinal preparations characterised by special physical form
C07C 217/28 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
74.
Antibody binding to chondroitin sulfate proteoglycan 5
The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The purpose of the present invention is to provide a bispecific antibody that binds to CD3, or a fragment of the bispecific antibody. The present invention pertains to: a bispecific antibody that binds to CD3, or a fragment of the bispecific antibody; DNA encoding the bispecific antibody or the bispecific antibody fragment; a vector including the DNA; a hybridoma and a transformant strain producing the bispecific antibody or the bispecific antibody fragment; a method for producing the bispecific antibody or the bispecific antibody fragment; a therapeutic and diagnostic agent containing the bispecific antibody or the bispecific antibody fragment; a therapeutic and diagnostic method using the bispecific antibody or the bispecific antibody fragment; and a detection or assay reagent containing the bispecific antibody or the bispecific antibody fragment.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The purpose of the present invention is to provide a bispecific antibody that binds to CD3, or a fragment of the bispecific antibody. The present invention pertains to: a bispecific antibody that binds to CD3, or a fragment of the bispecific antibody; DNA encoding the bispecific antibody or the bispecific antibody fragment; a vector including the DNA; a hybridoma and a transformant strain producing the bispecific antibody or the bispecific antibody fragment; a method for producing the bispecific antibody or the bispecific antibody fragment; a therapeutic and diagnostic agent containing the bispecific antibody or the bispecific antibody fragment; a therapeutic and diagnostic method using the bispecific antibody or the bispecific antibody fragment; and a detection or assay reagent containing the bispecific antibody or the bispecific antibody fragment.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals comprising antibodies, fragments of
antibodies and derivatives of antibodies; cells that
manufacture antibodies, fragments of antibodies and
derivatives of antibodies for medical purposes; cells for
medical purposes; pharmaceuticals. Contract manufacturing service in the field of antibodies,
fragments of antibodies, and derivatives of antibodies;
contract manufacturing service in the field of
pharmaceuticals comprising antibodies, fragments of
antibodies and derivatives of antibodies; contract
manufacturing service in the field of cells that manufacture
antibodies, fragments of antibodies and derivatives of
antibodies; contract extracting, refining, synthesizing,
manufacturing and preparing pharmaceuticals, agricultural
chemicals, and chemicals; providing information in the field
of manufacturing technology in the field of antibodies,
fragments of antibodies and derivatives of antibodies;
technical consultation in the field of manufacturing
technology in the field of antibodies, fragments of
antibodies and derivatives of antibodies; providing
information in the field of manufacturing technology in the
field of pharmaceuticals comprising antibodies, fragments of
antibodies and derivatives of antibodies; technical
consultation in the field of manufacturing technology in the
field of pharmaceuticals comprising antibodies, fragments of
antibodies and derivatives of antibodies; providing
information in the field of manufacturing technology in the
field of cells that manufacture antibodies, fragments of
antibodies and derivatives of antibodies; technical
consultation in the field of manufacturing technology in the
field of cells that manufacture antibodies, fragments of
antibodies and derivatives of antibodies; providing
technical information in the field of extracting, refining,
synthesizing, manufacturing and preparing pharmaceuticals,
agricultural chemicals, and chemicals; technical
consultation in the field of extracting, refining,
synthesizing, manufacturing and preparing pharmaceuticals,
agricultural chemicals, and chemicals. Development of antibodies, fragments of antibodies and
derivatives of antibodies for others; development of cells
that manufacture antibodies, fragments of antibodies and
derivatives of antibodies for others; development of host
cells for others; providing technical information in the
field of development of antibodies, fragments of antibodies
and derivatives of antibodies; providing technical
information in the field of development of cells that
manufacture antibodies, fragments of antibodies and
derivatives of antibodies; technical consultation in the
field of development of antibodies, fragments of antibodies
and derivatives of antibodies; technical consultation in the
field of development of cells that manufacture antibodies,
fragments of antibodies and derivatives of antibodies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of cancer and
immune-related diseases and disorders; pharmaceuticals for
use in the treatment of oncological disorders and diseases
and immune-related diseases and disorders; pharmaceutical
preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids, hormones in the nature of pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticals, namely, corticosteroids for treatment of hypopituitarism, of congenital adrenal hyperplasia, of rheumatoid arthritis, of rheumatic fever, of crohn's disease, and of chronic active hepatitis; pharmaceuticals, namely, estrogen preparations and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents; pharmaceuticals, namely, cataplasms being medical plasters for the treatment of bruises, lumbago and stiff shoulder; pharmaceuticals, namely, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents in the nature of vitamins for treating vitamin deficiencies, anti-coagulants, enzyme preparations for medical purposes for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, charred drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, moxa in the nature of cone or stick made of ground mugwort leaves for treating peptic ulcers; pharmaceuticals, namely, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; pharmaceuticals, namely, germination controllers and plant rearing agents in the nature of herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; pharmaceuticals, namely, antiseptics, pharmaceutical drugs in the nature of drug delivery agents in the form of coatings for tablets for the treatment of arteriosclerosis, oncostatic drugs in the nature of pharmaceutical products for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs in the nature of pharmaceutical products for the prevention and treatment of parkinsonism, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances and nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases; all the foregoing pharmaceuticals and vaccines comprising monoclonal antibodies
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
Inventor
Abe, Hiroshi
Iwai, Hiroto
Homma, Masakazu
Asano, Kana
Harada, Kenji
Yamamoto, Junichiro
Shinohara, Fumikazu
Motosawa, Keiichi
Kimura, Yasuaki
Nakamoto, Kosuke
Abstract
The present invention addresses the problem of providing a polynucleotide that has modified sites in a translation region but yet sustains the translation activity. This problem can be solved by a polynucleotide that contains a translation region from an imitation codon to a termination codon, wherein: the translation region comprises n codons; n is a positive integer of 2 or greater; the n codons each comprise the first, second and third nucleotides; and, in at least two codons among the n codons, the first nucleotide is a sugar-modified nucleotide.
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
KYOWA KIRIN CO., LTD. (Japan)
Inventor
Abe, Hiroshi
Iwai, Hiroto
Homma, Masakazu
Asano, Kana
Harada, Kenji
Yamamoto, Junichiro
Shinohara, Fumikazu
Motosawa, Keiichi
Kimura, Yasuaki
Nakamoto, Kosuke
Abstract
The present invention addresses the problem of providing a polynucleotide that has modified sites in a translation region but yet sustains the translation activity. This problem can be solved by a polynucleotide that contains a translation region from an imitation codon to a termination codon, wherein: the translation region comprises n codons; n is a positive integer of 2 or greater; the n codons each comprise the first, second and third nucleotides; and, in at least two codons among the n codons, the first nucleotide is a sugar-modified nucleotide.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; custom manufacturing, namely, contract refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of host cells; technical consultation in the field of custom manufacturing in the field of host cells; providing technical information in the field of contract manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; technical consultation in the field of manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Vitamins for use in the manufacture of food supplements, food and beverages; Oligosaccharides being chemicals for use in the manufacture of food supplement, food and beverages, medical food, milk for babies, powdered milk for babies; Lactic acid bacteria for use in the manufacture of food supplements, food and beverages
An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like:
n1 and n2 are the same or different, and each represents 0 or 1].
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 267/14 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 307/86 - Benzo [b] furansHydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
C07D 313/08 - Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 215/40 - Nitrogen atoms attached in position 8
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
C07D 311/68 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of cancer and immune-related diseases and disorders; pharmaceuticals for use in the treatment of oncological disorders and diseases and immune-related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Human pharmaceutical products for the treatment of cancer; human pharmaceutical products for the treatment of diseases and disorders of the immune system; human pharmaceuticals for use in the treatment of oncological diseases.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals comprising monospecific, bispecific or multispecific antibodies, fragments of monospecific, bispecific or multispecific antibodies and derivatives of monospecific, bispecific or multispecific antibodies for medical purposes; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies for medical purposes; cells for medical purposes Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of pharmaceuticals comprising antibodies, fragments of antibodies and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies; Custom manufacturing, namely, contract , refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of custom manufacturing in the field of antibodies, fragments of antibodies and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies and derivatives of antibodies; providing information in the field of custom manufacturing in the field of pharmaceuticals comprising antibodies, fragments of antibodies and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of pharmaceuticals comprising antibodies, fragments of antibodies and derivatives of antibodies; providing information in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies; providing technical information in the field of contract manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; technical consultation in the field of manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals Development of antibodies, fragments of antibodies and derivatives of antibodies for others; development of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies for others; development of host cells for others; providing technical information in the field of development of antibodies, fragments of antibodies and derivatives of antibodies; providing technical information in the field of development of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies; technical consultation in the field of development of antibodies, fragments of antibodies and derivatives of antibodies; technical consultation in the field of development of cells that manufacture antibodies, fragments of antibodies and derivatives of antibodies
The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
89.
Anti-BMP10 monoclonal antibody or fragment thereof
An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.
The object of the present invention is to provide a therapeutic agent for hyperphosphatemia capable sufficiently decreasing a serum phosphorus concentration with a small dose, and particles therefor. The present invention provides a therapeutic agent for hyperphosphatemia, which comprises, as an active ingredient, a particle containing a crosslinked polymer having a substituent containing a NRA1RA2 structure or a salt thereof, wherein the particle has an average particle diameter of 20 to 150 μm and a swelling rate of 9 to 16 mL/g (wherein RA1 and RA2 each independently represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an aminoalkyl group having 1 to 20 carbon atoms or a salt thereof, or the like).
The present invention provides, for example, an oligonucleotide derivative or a salt thereof comprising a circular oligonucleotide and a linear oligonucleotide, wherein the circular oligonucleotide and the linear oligonucleotide have base sequences complementary to each other, and form a complex via a hydrogen bond between the complementary base sequences, and a method for producing the same.
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand for a BET protein, and S represents a group represented by one formula selected from the group consisting of formulas (S1)-(S18).)
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1and L2 are the same or different and represent a low molecular ligand for a BET protein, and S represents a group represented by one formula selected from the group consisting of formulas (S1)-(S18).)
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
94.
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SYSTEMIC SCLERODERMA
As a novel and effective treatment for patients with systemic sclerodoma that may be accompanied by progressive hardening of the skin, the present invention provides a pharmaceutical composition that contains an IL-17 pathway inhibitor as an active ingredient and is for the treatment of systemic scleroderma that may be accompanied by progressive hardening of the skin. The IL-17 pathway inhibitor may be one or more IL-17RA antagonist and/or IL-23R antagonist and, in particular, may be one or more antibody or fragment of an antibody selected from the group that consists of brodalumab, secukinumab, ixekizumab, netakimab, bimekizumab, ustekinumab, tildrakizumab, risankizumab, mirikizumab, brazikumab, and guselkumab.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; pharmaceutical preparations; pharmaceutical
preparations for the treatment of skin diseases;
pharmaceutical preparations for the treatment of
inflammatory diseases, and autoimmune diseases;
pharmaceutical preparations for the treatment of dermatitis,
psoriasis, psoriatic arthritis, ankylosing spondylitis, and
axial spondylarthritis.
The present invention addresses the problem of providing: a DcR3 variant that has the binding activity (preferably neutralizing activity) of DcR3 to ligands and that exhibits improved in vivo kinetics and/or reduces the amount of generated aggregates compared to wild-type DcR3 when produced using mammal-derived cells as hosts; DNA for encoding the DcR3 variant; a vector including the DNA; a transformant obtained by introducing the vector; a variant production method using the transformant; and an agent that includes the variant as an active ingredient and that is for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease. In order to solve this problem, the present invention provides a DcR3 variant including part of DcR3 and part of a TNF superfamily molecule.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The present invention addresses the problem of providing: a DcR3 variant that has the binding activity (preferably neutralizing activity) of DcR3 to ligands and that exhibits improved in vivo kinetics and/or reduces the amount of generated aggregates compared to wild-type DcR3 when produced using mammal-derived cells as hosts; DNA for encoding the DcR3 variant; a vector including the DNA; a transformant obtained by introducing the vector; a variant production method using the transformant; and an agent that includes the variant as an active ingredient and that is for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease. In order to solve this problem, the present invention provides a DcR3 variant including part of DcR3 and part of a TNF superfamily molecule.
The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
An object of the present invention is to provide a novel IL-2 variant which has improved selectivity for IL-2Rαβγ and selectively activates Tregs. The present invention relates to an IL-2 variant, a method for producing the IL-2 variant, a composition and a therapeutic agent for an immune disease, comprising the IL-2 variant, a method for increasing selectivity of IL-2 for IL-2Rαβγ, a method for improving an affinity of IL-2 for an IL-2Rα subunit, a method of reducing an affinity of IL-2 for at least one of an IL-2Rβ subunit and an IL-2Rγ subunit, and a method for selectively activating regulatory T cells.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The purpose of the present invention is to provide: a method for purifying an antibody in non-adsorption mode using an inorganic compound that contains silicon dioxide and aluminum oxide, as a method for producing an antibody at a lower cost than the prior art; a method for producing an antibody that includes the purification method; and an antibody, etc., produced by the production method. The present invention pertains to a method for purifying an antibody in non-adsorption mode using an inorganic compound that contains silicon dioxide and aluminum oxide, a method for producing an antibody that includes the purification method, and an antibody produced by the production method.
